Altace is a drug owned by King Pharmaceuticals Inc Sub Pfizer Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 30, 2020. Details of Altace's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7368469 | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
Aug, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Altace's patents.
Latest Legal Activities on Altace's Patents
Given below is the list of recent legal activities going on the following patents of Altace.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Oct, 2019 | US7368469 |
| Post Issue Communication - Certificate of Correction | 25 Jun, 2008 | US7368469 |
| Recordation of Patent Grant Mailed Critical | 06 May, 2008 | US7368469 |
| Patent Issue Date Used in PTA Calculation Critical | 06 May, 2008 | US7368469 |
| Issue Notification Mailed Critical | 16 Apr, 2008 | US7368469 |
| Dispatch to FDC | 31 Mar, 2008 | US7368469 |
| Application Is Considered Ready for Issue Critical | 26 Mar, 2008 | US7368469 |
| Mail Miscellaneous Communication to Applicant | 26 Mar, 2008 | US7368469 |
| Miscellaneous Communication to Applicant - No Action Count | 20 Mar, 2008 | US7368469 |
| Issue Fee Payment Verified Critical | 29 Feb, 2008 | US7368469 |
US patents provide insights into the exclusivity only within the United States, but Altace is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Altace's family patents as well as insights into ongoing legal events on those patents.
Altace's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Altace's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 30, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Altace Generic API suppliers:
Ramipril is the generic name for the brand Altace. 17 different companies have already filed for the generic of Altace, with Zydus Pharms Usa Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Altace's generic
How can I launch a generic of Altace before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Altace's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Altace's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Altace -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 1.25 mg, 2.5 mg, 5 mg and 10 mg |
About Altace
Altace is a drug owned by King Pharmaceuticals Inc Sub Pfizer Inc. It is used for reducing the risk of myocardial infarction, stroke, and death. Altace uses Ramipril as an active ingredient. Altace was launched by King Pfizer in 2007.
Approval Date:
Altace was approved by FDA for market use on 27 February, 2007.
Active Ingredient:
Altace uses Ramipril as the active ingredient. Check out other Drugs and Companies using Ramipril ingredient
Treatment:
Altace is used for reducing the risk of myocardial infarction, stroke, and death.
Dosage:
Altace is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| 1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
Altace is a drug owned by King Pharmaceuticals Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 30, 2020. Details of Altace's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7368469 | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
Aug, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Altace's patents.
Latest Legal Activities on Altace's Patents
Given below is the list of recent legal activities going on the following patents of Altace.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Oct, 2019 | US7368469 |
| Post Issue Communication - Certificate of Correction | 25 Jun, 2008 | US7368469 |
| Recordation of Patent Grant Mailed Critical | 06 May, 2008 | US7368469 |
| Patent Issue Date Used in PTA Calculation Critical | 06 May, 2008 | US7368469 |
| Issue Notification Mailed Critical | 16 Apr, 2008 | US7368469 |
| Dispatch to FDC | 31 Mar, 2008 | US7368469 |
| Application Is Considered Ready for Issue Critical | 26 Mar, 2008 | US7368469 |
| Mail Miscellaneous Communication to Applicant | 26 Mar, 2008 | US7368469 |
| Miscellaneous Communication to Applicant - No Action Count | 20 Mar, 2008 | US7368469 |
| Issue Fee Payment Verified Critical | 29 Feb, 2008 | US7368469 |
US patents provide insights into the exclusivity only within the United States, but Altace is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Altace's family patents as well as insights into ongoing legal events on those patents.
Altace's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Altace's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 30, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Altace Generic API suppliers:
Ramipril is the generic name for the brand Altace. 17 different companies have already filed for the generic of Altace, with Zydus Pharms Usa Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Altace's generic
How can I launch a generic of Altace before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Altace's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Altace's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Altace -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 1.25 mg, 2.5 mg, 5 mg and 10 mg |
About Altace
Altace is a drug owned by King Pharmaceuticals Llc. It is used for reducing the risk of myocardial infarction, stroke, and death. Altace uses Ramipril as an active ingredient. Altace was launched by King Pharms Llc in 1991.
Approval Date:
Altace was approved by FDA for market use on 28 January, 1991.
Active Ingredient:
Altace uses Ramipril as the active ingredient. Check out other Drugs and Companies using Ramipril ingredient
Treatment:
Altace is used for reducing the risk of myocardial infarction, stroke, and death.
Dosage:
Altace is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.25MG | CAPSULE | Prescription | ORAL |
| 2.5MG | CAPSULE | Prescription | ORAL |
| 5MG | CAPSULE | Prescription | ORAL |
| 10MG | CAPSULE | Prescription | ORAL |